Supplementary table 1: WHO trial registration data set.

WHO Trial Registration Data Set	
Primary registry and trial identifying number	**EudraCT number:** 2021-000289-13 **Netherlands trial register:** NL9723
Date of registration in primary register	20th July 2021
Protocol version	Version 3, date 27-05-2021
SPIRIT guidelines data set for clinical trials	Attached as a supplementary file
Source of monetary or material support	F.R. van 't Land, Study Coordinator Department of Surgery Erasmus MC University Medical Center, Rotterdam, The Netherlands f.vantland@erasmusmc.nl
Primary Sponsor	Erasmus MC University Medical Center, Department of Pulmonary Medicine, Represented by Prof. Dr. J.G.J.V. Aerts, Rotterdam, The Netherlands
Contact for Public Queries	F.R. van 't Land, Study Coordinator Department of Surgery Erasmus MC University Medical Center, Rotterdam, The Netherlands f.vantland@erasmusmc.nl
Contact for Scientific Queries	C. H. J. van Eijck, Coordinating investigator Department of Surgery Erasmus MC University Medical Center, Rotterdam, The Netherlands. c.vaneijck@erasmusmc.nl
Public Title	Combining dendritic cell vaccination and anti-CD40 agonist for metastatic pancreatic cancer patients
Scientific Title	Safety and tumor-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 Trial)
Countries of Recruitment	The Netherlands
Health Condition(s) or Problem(s) Studied	Metastatic pancreatic cancer
Intervention(s)	Vaccinations with autologous dendritic cells pulsed with an allogeneic mesothelioma tumor cell lysate (MesoPher) Anti-CD40 agonist (mitazalimab)
Key Inclusion and Exclusion Criteria	See supplementary table 2
Study Type	Open-label, single-center, phase I dose finding study

Date of First Enrollment	30th August 2021
Sample Size	Minimum of 12, maximum of 18 patients
Recruitment Status	Recruiting
Primary Outcome(s)	Safety and tolerability of MesoPher/mitazalimab combination therapy
Key Secondary Outcomes	Assessment of immune-responses upon therapy Radiographical response rate as defined by RECIST version 1.1 and iRECIST
Ethics Review	Permission for the trial conduct was given by the Central Committee on Research Involving Human Subjects and the Medical Ethics Committee of the Erasmus MC University Medical Center Rotterdam